First in Men Study: BIOMAG-I

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 116 participants.

Also called NCT04157153

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 116 participants (enrolled count) (from the registry)
Sponsor
  • Biotronik AG Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04157153
Other papers using this trial's data
  • The Impact of Underlying Plaque Characteristics Following the Third-Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12-Months Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025-06 DOI, PubMed 40091374, PMC12159389 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Austria, Belgium, Germany, Netherlands, Poland, Spain, Sweden, Switzerland (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04157153. Allocation not applicable; no masking; primary purpose treatment. Start 2020-04-27 (actual); primary completion 2022-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
First in Men Study: BIOMAG-I
Intervention (Device)
Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
Lead sponsor
Biotronik AG (class: industry)

Record details

Record id
cardio:ct-nct04157153
Content hash
e0b393a8779e2b6d21279111441b0943640a74b1f719b213dd831626f9a94e2c